Infection Control Market Development Trends, Driving Forces, Opportunities & Potential 2027

 Prevalence of chronic diseases, increased surgical procedures, and the high incidence of hospital-acquired infections is propelling the infection control and prevention market.

Market Size – USD 19.82 billion in 2019, Market Growth - CAGR of 6.5%, Market Trends –The outbreak of novel coronavirus.

The Global Infection Control Market was valued at USD 19.82 billion in 2019 and is estimated to exceed USD 31.99 Billion in terms of remunerations, delivering a CAGR of  6.5% through 2027. The market growth is driven by the high incidence rate of HAIs. The CDC (Centers for Disease Control) estimates that HAIs infect nearly 1.7 million people and leads to 99,000 deaths annually.

The developed economies are likely to offer several growth opportunities for the infection control products market due to a better level of awareness and increased focus on self-hygiene among people, especially after the COVID-19 pandemic. 

Expansion of the geriatric population base, prevalence of life-threatening diseases such as cancer, diabetes, obesity, heart, and respiratory diseases is fuelling the demand for infection control products. Also, the implementation of strict government policies to control infections and will support infection control market growth.

Get a sample copy of the report @ https://www.reportsanddata.com/sample-enquiry-form/944

The COVID-19 impact:

The WHO is encouraging masses to take more aggressive steps against infections since the COVID-19 outbreak. Medical settings like hospitals where the infected patients are being treated are suggested to take special care for containing the spread of the deadly virus. The disinfectants and preservatives market is gaining major traction during the pandemic and is likely to foster infection control industry size during the forecast period. Moreover, surging growing adoption of disinfectants and sanitizers as a preventive measure may change the market dynamics in the coming years.

To identify the key trends in the industry, click on the link below@ https://www.reportsanddata.com/report-detail/global-infection-control-market

Further key findings from the report suggest

• Infection control and prevention market is poised to witness substantial growth over the projected timeframe. Hospital-acquired infections are a leading cause of avertible death globally. The transmission of disease is dependent on the physical environment. The introduction of novel technologies in healthcare facilities to reduce or eliminate the environmental route of disease transmission will favor infection control and prevention market growth. The UV surface disinfection is one of the latest technologies with substantial potential.

• On the basis of application, the personal protective equipment segment is experiencing major growth due to concern for worker’s safety and is thereby augmenting the infection control products market. Usage of these equipment in medical settings can prevent the spread of infections to healthy staff workers from exposed patients. 

• Based on end-use, the hospitals and clinics segments are estimated to witness maximum growth over the analysis period. The robust growth can be attributed to the rising incidence of infection and prevalence of diseases, prompting medical facilities to adopt infection control products for sanitization purposes.

• In the regional landscape, the Asia Pacific region is expected to hold a major share in the infection control market over the analysis period due to high investment in healthcare infrastructure development.

• North America is experiencing the highest adoption rate of infection control and prevention products due to high disposable income and consumer awareness regarding mass spread of infections. The presence of major industry players in the region is also encouraging market growth.

• Europe is forecast to exhibit a growth rate of 6.7% through 2027 on account of the growth of the healthcare industry in the region.

• Key players contributing to the global infection control statistics are Getinge AB, Steris PLC, Belimed AG, Advanced Sterilization Products, MMM Group, Matachana Group, Ecolab, Inc., Pal International, Miele Group, and 3M Company, among others.

The infection control report provides a thorough insight into the competitive landscape and market drivers. For the study, Reports and Data has segmented the global Infection Control Market on the basis of product, application, end-users, and region:

Product Outlook (Revenue, USD Billion; 2017-2027)

• Disinfectors
• Washers
• Flushes
• Sterilization Equipment
• Endoscope Reprocessors
• Heat Sterilization Equipment
• Radiation Sterilization Equipment
• Low-Temperature Sterilization Equipment
• Filtration Sterilization Equipment
• Liquid Sterilization Equipment
• Others

Application Outlook (Revenue, USD Billion; 2017-2027)

• Infectious Waste Disposal
• Sterilization Consumables
• Disinfectant
• Personal Protective Equipment

End Users Outlook (Revenue, USD Billion; 2017-2027)

• Hospital and Clinics
• Life Science Industry
• Medical Device Companies
• Pharmaceutical Companies
• Food Industry

Request a discount on the report @ https://www.reportsanddata.com/discount-enquiry-form/944

Regional Outlook (Revenue, USD Billion; 2017-2027)

• North America
  • U.S
  • Canada
• Europe
  • Germany
  • U.K
  • France
  • BENELUX
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • South Korea
  • Rest of APAC
• Latin America
  • Brazil
  • Rest of LATAM
• MEA
  • Saudi Arabia
  • UAE
  • Rest of MEA

Thank you for reading our report. The customization of the report is available as per your research needs. Please get in touch with us, and our team will ensure you get the report tailored as per your requirements.

Related Report:

1. Biocide Market Size, Share & Analysis, By Product Type, By Application, By Region And Segment Forecasts, 2020-2027

2. Calcium Propionate Market Size, Share & Analysis, By Product Type, By Contrast Type And Segment Forecasts To 2027

Point of Care (PoC) Diagnostics Market Global Industry Statistics & Regional Outlook to 2027

 According to the recent marketing research of Reports and Data, the global Point of Care (PoC) Diagnostics market size was estimated to be USD 26.28 Billion in 2019 and is anticipated to surpass USD 55.35 Billion by year 2027, registering a CAGR of 9.6%.

The Centers for Disease Control and Prevention, in U.S. estimates 100 million adults are affected by diabetes or pre-diabetes at the present. Cardiovascular diseases (CVD) account for about 800,000 deaths within the country. On a mean, U.S. records the death of 1 person every 40 seconds from CVD. It also causes 3.9 million deaths in Europe and around 1.8 million deaths within the European Union.

Point-of-care (POC) diagnostics is a medical diagnostic assay that allows physicians and medical staff to accurately attain lab-quality diagnostic leads to real-time. In other words, the results are available within minutes instead of hours. With portable blood analysers, testing near patient streamlines the diagnostic process and aids to make sure patients receive the foremost effectual and efficient care when and where needed. Point-of-care (POC) diagnostic testing allows medical staff to form speedy treatment decisions when analysing a patient’s condition or monitoring a treatment reaction. By streamlining the testing process, physicians can specialise in providing effective, quality patient care.

Get a sample copy of the report @ https://www.reportsanddata.com/sample-enquiry-form/1507

Point of Care (PoC) Diagnostics Market Dynamics
Near patient testing allows quite just bedside testing. It enables clinicians to enhance efficiency and productivity. These diagnostic tools are possibly costlier than traditional ones but are more accurate and even lower staff burden by driving the main target back to the patient. Major developments within the field of Point-of-Care (PoC) diagnostics include PixCell Medical’s acceptance of the FDA 510(k) approval for its POC the HemoScreen Haematology Analyser, in 2018. HemoScreen Haematology Analyser enables physicians to form accurate decisions with increased rapidity.

Predominance of infectious diseases, swelling occurrence of target diseases, and stronger preference for home healthcare in developing economies across the planet are increasing the adoption of PoC diagnostics products. Greater investment by public organizations is additionally acting as driving factor for the expansion of the market. As an example , in 2018, the Massachusetts Medical Device Development Center used a USD 7.9 million grant from the National Institute of Health (NIH) to determine a M2D2 which essentially helps inventors leading promising new PoC devices and technologies handling heart, lung, blood and sleep disorders.

Point of Care (PoC) Diagnostics Market: Regional Outlook

North America is predicted to account for the 41.1% of the global Point of Care (PoC) Diagnostics market due to CVD prevalence and chronic disorders due to unhealthy lifestyle. Rapid FDA approvals and streamlined government regulations related to development of healthcare will also supplement the growth. Europe Point of Care (PoC) Diagnostics market size follows that of North America with a share of 33.1% thanks to the increased adoption of these devices, rise in awareness about medical innovative, increased applications of point of care diagnostic devices, and rapidly aging population including increase in incidences of diabetes and liver diseases.

Impact of COVID-19 on Point of Care (PoC) Diagnostics Market:

COVID-19 has affected various business aspects and therefore the healthcare sector has been the most considerably impacted by the crisis. The WHO has declared COVID-19 to be a worldwide pandemic and therefore the healthcare industry has resorted to variety of emergency undertakings to assist the overall population in fighting the deadly disease. While hospitals and clinics are filled to capacity, trying to assist ailing patients, most patients are asked to remain away from healthcare institutions if not faced with dire emergency as hospitals are currently highly contagious and the coronavirus can negatively impact the health condition of weak individuals. The growth of PoC Diagnostics market is predicted to register a huge surge in demand as COVID-19 crisis creates a substantial opportunity for near patient tests.

To identify the key trends in the industry, click on the link below @ https://www.reportsanddata.com/report-detail/point-of-care-poc-diagnostics-market

Point of Care (PoC) Diagnostics Market: Key Players

• Abbott
• F. Hoffmann-La Roche
• Siemens Healthineers

Report Highlights:

• Detailed overview of the market
• Evolving Point of Care (PoC) Diagnostics market dynamics
• In-depth Point of Care (PoC) Diagnostics market classification
• Historical, present, and anticipated Point of Care (PoC) Diagnostics market size and share in terms of volume and value
• Recent Point of Care (PoC) Diagnostics market trends and advances
• Competitive landscape
• Strategies adopted by key players and products portfolio
• Segments, sub-segments, and geographic regions exhibiting growth prospects
• A neutral and global perspective on Point of Care (PoC) Diagnostics market performance

Point of Care (PoC) Diagnostics Market: Segmentation

For the purpose of the study, this Reports and Data has segmented the Global Point of Care (PoC) Diagnostics Market on the basis of product type, platform type, prescription mode, end user and the regional outlook:

Product Type (Revenue, USD Million; 2017–2027)

• Glucose Monitoring Products
  • Strips
  • Meters
  • Lancets & Lancing Devices
• Cardiometabolic Testing Products
  • Cardiac Marker Testing Products
  • Blood Gas/Electrolytes Testing Products
  • HBA1C Testing Products
• Infectious Disease Testing Products
  • Influenza Testing Products
  • HIV Testing Products
  • Hepatitis C Testing Products
  • Sexually Transmitted Disease (STD) Testing Products
  • Healthcare-Associated Infection (HAI) Testing Products
  • Respiratory Infection Testing Products
  • Tropical Disease Testing Products
  • Other Infectious Disease Testing Products
• Coagulation Testing Products
• PT/INR Testing Products
• Activated Clotting Time (ACT/APTT) Testing Products
• Pregnancy and Fertility Testing Products
• Pregnancy Testing Products
• Fertility Testing Products
• Tumour/Cancer Marker Testing Products
• Urinalysis Testing Products
• Cholesterol Testing Products
• Haematology Testing Products
• Drugs-of-Abuse Testing Products
• Fecal Occult Testing Products
• Other POC Products

Platform Type (Revenue, USD Million; 2017–2027)

• Agglutination assays
• Biosensors
• Dipsticks
• Lateral Flow Assays
• Microfluidics
• Molecular Diagnostics
• Solid phase

Prescription Mode (Revenue, USD Million; 2017–2027)

• Prescription-based Testing
• OTC Testing

End User (Revenue, USD Million; 2017–2027)

• Professional Diagnostic Centres
• Clinical Laboratories (Outpatient Healthcare & Ambulatory Care Settings)
• Hospitals/Critical Care Centres
• Home Care
• Research Laboratories
• Other End Users

Request a discount on the report @ https://www.reportsanddata.com/discount-enquiry-form/1550

Regional Outlook (Revenue, USD Million; 2017–2027)

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • Spain
  • France
  • Italy
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • Rest of Asia-Pacific
• Latin America
  • Brazil
  • Mexico
• Middle East and Africa (MEA)

Thank you for reading our report. The customization of the report is available as per your research needs. Please get in touch with us, and our team will ensure you get the report tailored as per your requirements.

Similar Report:

1. Urinalysis Market Size, Trends & Analysis, By Product, By Application, By End-Use Vertical, By Region, Segment Forecasts To 2027

2. Diagnostic Biomarkers Market Size, Trends & Analysis, By Product, By Form and By Application, Forecasts To 2027

Cancer Immunotherapy Market with Emerging Trends, Global Scope and Demand 2020 to 2027

Cancer Immunotherapy Market: An Overview

The Global Cancer Immunotherapy Market size is forecast to surpass USD 153.03 billion in 2027 from USD 78.04 billion in 2019, delivering a CAGR of 10.1% over the forecast period. Increased cancer incidence, higher adoption of immunotherapy drugs as compared to standard treatments, increasing investments for monoclonal antibodies and biosimilars development, and more streamlined drug approval scenario, are the key factors driving global cancer immunotherapy market growth.

Government and cancer research institutes are investing in research and development in various cell therapies would drive the market further. As an example , the University of Texas MD Anderson Cancer Center announced positive outcomes to its Phase 1/2a clinical trials for CAR-NK cell therapy for chronic leukemia and Hodgkin’s Lymphoma. Also, Kite, a Gilead company, announced that KTE-X19, their CAR- T therapy, has been authenticated under European Medicines Agency. However, the complicated procedures conducted in cell therapies could be time-consuming and expensive, and this would be a restraint for the market. Strict government regulations are expected to hamper the market over the forecast period.

Get a sample copy of the report @ https://www.reportsanddata.com/sample-enquiry-form/1550

Cancer Immunotherapy Market Dynamics

A paradigm shift from traditional chemotherapies to immunotherapies has created a rewarding growth scope for the cancer immunotherapy industry. Immuno-oncology has exhibited encouraging results with lower toxicity and better survival rates. Increasing effectiveness and efficacy of stem cell therapies will boost patient preference for immunotherapy.

In 2018, a report estimated that the global cancer burden recorded 18.1 million new cases and 9.6 million deaths globally. The rising occurrence has prompted various government and cancer research institutes to intensify investment in research & development of varied sorts of cell therapies for the treatment of cancer.

Moreover, various sorts of immunotherapies, like immunomodulators and CAR T-cell therapy, are being examined for improved outputs. The continuing research and new approvals are expected to foster cancer immunotherapy market share over the forecast period.

However, immunotherapy side effects can range from mild up to life-threatening cases owing to certain circumstances of the patients’ health. Severe cases of side effects can occur when an overstimulated immune reaction is experienced. Comparatively, the traditional targeted therapy or chemotherapy can adversely attack non-cancerous cells, leading to hair loss, nausea, and a few other mild to moderate side effects.


To identify the key trends within the industry, click on the link below@ https://www.reportsanddata.com/report-detail/cancer-immunotherapy-market

Cancer Immunotherapy Market: Regional Outlook

North America dominated the cancer immunotherapy market with a revenue of USD 66.21 billion in 2019 and is estimated to register a rate of growth of 14.1% through 2027. The expansion is often attributed to rising technological advancements within the medical field, like the event of CRISPR for cancer treatment.

The cancer immunotherapy market report in Europe estimates that the industry will exhibit a CAGR of 13% over the analysis period on account of the introduction of favorable medical reimbursement policies within the region.

The cancer immunotherapy market analysis within the Asia Pacific is anticipated to witness a maximum rate of growth of 17.2% over the forecast period on account of the presence of a huge patient pool affected by various sorts of cancer in India and China.

Cancer Immunotherapy Market: Key Players

• Bristol-Myers Squibb
• Celgene Corporation
• Novartis International Ag, Amgen Inc.
• Merck & Co. Inc.
• Seattle Genetics Inc
• Printegra, Janssen Global Services, LLC
• Gristone Oncology, and Inc
• Pfizer Inc.

Impact of COVID-19 on Cancer Immunotherapy Market:

After the COVID-19 outbreak, a serious concern among the medical profession was contemplating if using cancer immunotherapy in COVID-19 patients would produce to any complications or worsen their conditions. These concerns were set aside by a preliminary analysis at the University of Cincinnati Cancer Center. The initial data indicated that immunotherapy doesn't radically worsen the complications for COVID-19-positive patients with cancer. However, immunotherapy did not prove to be very effective either and therefore put aside as a possible treatment for coronavirus.

Another dramatic change within the healthcare sector occurred by popularity of digitalization. Worldwide lockdowns and therefore the general panic surrounding the rapid spread of the infection made it challenging for patients to go to hospitals, which, in many cases, were treating COVID-19 patients. Thus, to avoid going to hospitals and get access to healthcare, patients and doctors resorted to telemedicine. The crisis created by COVID-19 helped to bring light the benefits of tele-oncology and the way it can curb the fatality of cancer in rural areas where access to healthcare is limited. Cancer immunotherapy market analysis indicates that tele-oncology will open up new growth prospects for the market in the future.

Request a discount on the report @ https://www.reportsanddata.com/discount-enquiry-form/1550

Report Highlights:

·         Detailed overview of the market

·         Evolving cancer immunotherapy market dynamics

·         In-depth cancer immunotherapy market classification

·         Historical, present, and anticipated cancer immunotherapy market size and share in terms of volume and value

·         Recent cancer immunotherapy market trends and advances

·         Competitive landscape

·         Strategies adopted by key players and products portfolio

·         Segments, sub-segments, and geographic regions exhibiting growth prospects

·         A neutral and global perspective on cancer immunotherapy market performance

 Cancer Immunotherapy Market: Segmentation

For the purpose of this report, Reports and Data has segmented into the Global Cancer Immunotherapy Market on the basis of technology, application, end use, and region:

Technology Outlook (Revenue, USD Billion; 2017-2027)

• Monoclonal Antibodies
• Vaccines
• Checkpoint Inhibitors
• Cell Therapies
• Immune System Modulators
• Adoptive Cell Transfer
• Cytokines
• Others

Application Outlook (Revenue, USD Billion; 2017-2027)

• Head & Neck Cancer
• Blood Cancers
• Liver Cancer
• Lung Cancer
• Breast Cancer
• Prostate Cancer
• Melanoma
• Others

End Use Outlook (Revenue, USD Billion; 2017-2027)

• Cancer Research Centers
• Hospitals
• Clinics
• Others

Regional Outlook (Revenue, USD Billion; 2017-2027)

• North America
• U.S.
• Europe
• Germany
• U.K.
• France
• Spain
• Italy
• Rest of Europe
• Asia Pacific
• China
• India
• Japan
• South Korea
• Rest of Asia Pacific
• Middle East & Africa
• Latin America
• Brazil

Thank you for reading our report. The customization of the report is available as per your research needs. Please get in touch with us, and our team will ensure you get the report tailored as per your requirements.

Related Report:

1. Pressure Ulcers Treatment Market Size, Share & Analysis, By Material, By End-User, By Application, By Region Forecast To 2027

2. Facial Erythema Therapeutics Market Trends, Share & Size, By Product Type, By Application, By End-Use, By Region Forecast To 2027